Cytokines and immunity to viral infections

Immunological Reviews

Volumn 159, Issue , 1997, Pages 119-135

  Ramshaw, Ian A ^a   Ramsay, Alistair J ^a   Karupiah, Gunasegaran ^a   Rolph, Michael S ^b   Mahalingam, Surendran ^a   Ruby, Janet C ^c  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^b MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CHEMOKINE; CYTOKINE; CYTOKINE RECEPTOR; GAMMA INTERFERON; GLYCOPROTEIN GP 39; INTERFERON RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; PERFORIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; CONTROLLED STUDY; ECTROMELIA VIRUS; GENE DISRUPTION; HOST RESISTANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE; VACCINIA VIRUS; VIRUS IMMUNITY; VIRUS RECOMBINANT; VIRUS VIRULENCE;

EID: 0030711669     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1997.tb01011.x     Document Type: Review

References (96)

1. Wong GHW, Clark-Lewis U, McKimm-Breschkin JL, Harris AW, Schrader JW. Interferon-γ induces enhanced expression of Ia and H-2 antigens on B lymphoid, macrophage and myeloid cell lines. J Immunol 1983;131:788-793.
2. Bukowski JF, Welsh RM. Interferon enhances the susceptibility of virus-infected fibroblasts to cytotoxic T cells. J Exp Med 1985;161:257-262.
3. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994;76:301-314.
4. Croft M. Activation of naive, memory and effector cells. Curr Opin Immunol 1994;6:431-437.
5. Stout RD. Macrophage activation by T cells: cognate and non-cognate signals. Curr Opin Immunol 1993;5:398-403.
6. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell 1994;76:241-251.
7. Zinkernagel RM. Immunity to viruses. In: Paul WE, ed. Fundamental immunology. New York: Raven Press; 1993. p. 1211-1250.
8. Czarniecki CW, Fennie CW, Powers DB, Estell DA. Synergistic antiviral and antiproliferative activities of Eschcrichia coli-derived human alpha, beta, and gamma interferons. J Virol 1984;49:490-496.
9. Wong GHW, Goeddel D. Tumor necrosis factors α and β inhibit virus replication and synergise with interferons. Nature 1986;323:819-822.
10. Ramshaw IA, Andrew ME, Phillips SM, Boyle DB, Coupar BE. Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection. Nature 1987;329:545-546.
11. Karupiah G, et al. Elevated natural killer cell responses in mice infected with recombinant vaccinia virus encoding murine IL-2. J Immunol 1990;144:290-298.
12. Karupiah G, Blanden RV, Ramshaw IA. Interferon gamma is involved in the recovery of athymic nude mice from recombinant vaccinia virus/interleukin 2 infection. J Exp Med 1990;172:1495-1503.
13. Kohonen-Corish MR, King NJ, Woodhams CE, Ramshaw IA. Immunodeficient mice recover from infection with vaccinia virus expressing interferon-gamma. Eur J Immunol 1990;20:157-161.
14. Sambhi SK, Kohonen-Corish MR, Ramshaw IA. Local production of tumor necrosis factor encoded by recombinant vaccinia virus is effective in controlling viral replication in vivo. Proc Natl Acad Sci USA 1991;88:4025-4029.
15. + T cells is dependent on interferon-gamma. Lymphokine Cytokine Res 1991;10: 353-358.
16. Ramsay AJ, Ruby J, Ramshaw IA. A case for cytokines as effector molecules in the resolution of virus infection. Immunol Today 1993;14:155-157.
17. Ramsay AJ, et al. The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 1994;264:561-563.
18. Leong KH, Ramsay AJ, Boyle DB, Ramshaw IA. Selective induction of immune responses by cytokines co-expressed in recombinant fowlpox virus. J Virol 1994;68:8125-8130.
19. Ramsay AJ, Kohonen-Corish MR. Interleukin-5 expressed by a recombinant virus vector enhances specific mucosal IgA responses in vivo. Eur J Immunol 1993;23:3141-3145.
20. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995;13:251-276.
21. Huang S, et al. Immune response in mice that lack the interferon-γ receptor. Science 1993;259:1742-1745.
22. Afonso LC, Scharton TM, Vieira LQ, Wysocka M, Trinchieri G, Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 1994;263:235-237.
23. Wynn TA, et al. IL-12 enhances vaccine-induced immunity to Schistosomes by augmenting both humoral and cell-mediated immune responses against the parasite. J Immunol 1996;157:4068-4078.
24. Manetti R, et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 1993;177:1199-1204.
25. Wang ZE, et al. Interferon gamma-independent effects of interleukin 12 administered during acute or established infection due to Leishmania major. Proc Natl Acad Sci USA 1994;91: 12932-12936.
26. Morrissey PJ, et al. Recombinant interleukin 7, a pre-B cell growth factor, has co-stimulatory activity on purified mature T cells. J Exp Med 1989;169:707-716.
27. Welch PA, Namen AE, Goodwin RG, Armitage R, Cooper MD. Human IL-7: a novel T cell growth factor. J Immunol 1989;143:3562-3567.
28. Alderson MR, Sassenfeld HM, Widmer MB. Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood. J Exp Med 1990;172:577-587.
29. + natural killer cells. A comparative study. J Immunol 1991;147:2208-2214.
30. Leong KH, Ramshaw IA, Ramsay AJ. Interleukin-7 enhances cell-mediated immune responses in vivo in an interleukin-2-dependent manner. Viral Immunol 1997;10:1-9.
31. Rich BE, Leder P. Transgenic expression of IL-7 restores T-cell populations in nude mice. J Exp Med 1995;181:1223-1228.
32. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation and death. Cell 1994;76:959-962.
33. Armitage RJ. Tumor necrosis factor receptor superfamily members and their ligands. Curr Opin Immunol 1994;6:407-413.
34. Bazan JF. Emerging families of cytokines and receptors. Curr Biol 1993;3:603-606.
35. Beutler B, van Huffel C. Unraveling function in the TNF ligand and receptor families. Science 1994;264:667-668.
36. Ruby J, Bluethmann H, Aguet M, Ramshaw IA. CD40 ligand has potent antiviral activity. Nat Med 1995;1:437-441.
37. Foy TM, Aruffo A, Bajorath J, Buhlmann JE, Noelle RJ. Immune regulation by CD40 and its ligand gp39. Annu Rev Immunol 1996;14:591-617.
38. Hess S, Engelmann H. A novel function of CD40: induction of cell death in transformed cells. J Exp Med 1996;183:159-167.
39. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell 1994;76:17-27.
40. Erard F, Wild M-T, Garcia-Sanz JA, Le Gros G. Switch of CD8 T cells to noncytolytic CD8-CD4-cells that make TH2 cytokines and help B cells. Science 1993;260:1802-1805.
41. Widmer MB, Grabstein KH. Regulation of cytolytic T-lymphocyte generation by B-cell stimulatory factor. Nature 1987;326:795-798.
42. Horohov DW, Crim JA, Smith PL, Siegel JP. IL-4 (B cell-stimulatory factor 1) regulates multiple aspects of influenza virus-specific cell-mediated immunity. J Immunol 1988;141:4217-4223.
43. + T cells secreting Th1 or Th2 cytokines. Immunity 1995;2:271-279.
44. + cells can switch to interleukin 5 production and induce airway eosinophilia. J Exp Med 1995;181:1229-1233.
45. H2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993;14:107-111.
46. Clerici M, Shearer GM. The Th1-Th2 hypothesis of HIV infection: new insights. Immunol Today 1994;15:575-581.
47. Tang Y-W Graham BS. Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus. J Clin Invest 1994;94:1953-1958.
48. Connors M, Giese NA, Kulkarni AB, Firestone C-Y, Morse HC III, Murphy BR. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol 1994;68:5321-5325.
49. Gao JL, Murphy PM. Human cytomegalovirus open reading frame US28 encodes a functional β chemokine receptor. J Biol Chem 1994;269:28539-28542.
50. MacDonald MR, Li XY, Virgin HW. Late expression of a beta chemokine homolog by murine cytomegalovirus. J Virol 1997;71:1671-1678.
51. Deng H, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381:661-666.
52. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-877.
53. Farber JM. A new human member of the chemokine family of cytokines. Biochem Biophys Res Commun 1993;192: 223-230.
54. Vanguri P, Farber JM. Identification of CRG-2: an interferon -inducible mRNA predicted to encode a murine monolcine. J Biol Chem 1990;265:15049-15057.
55. Luster AD, Unkeless JC, Ravetch JV. γ-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 1985;315:672-676.
56. Liao F, Rabin RL, Yannelli JR, Koniaris LG, Vanguri P, Farber JM. Human mig chemokine: biochemical and functional characterization. J Exp Med 1995;182:1301-1314.
57. Taub DD, et al. Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med 1993;177:1809-1814.
58. Loetscher M, et al. Chemokine receptor specific for IP-10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 1996;184:963-969.
59. Amichay D, Gazzinelli RT, Karupiah G, Moench TR, Sher A, Farber JM. Genes for chemokines mumig and crg-2 are induced in protozoan and viral infections in response to IFN-γ with patterns of tissue expression that suggest nonredundant roles in vivo. J Immunol 1996;157:4511-4520.
60. Leist TP, Eppler M, Zinkernagel RM. Enhanced virus replication and inhibition of lymphocytic choriomeningitis virus disease in anti-gamma interferon-treated mice. J Virol 1989;63:2813-2819.
61. Karupiah G, Fredrickson TN, Holmes KL, Khairallah LH, Buller RML. Importance of interferons in recovery from mousepox. J Virol 1993;67:4214-4226.
62. Müller U, et al. Functional role of type I and type II interferons in antiviral defense. Science 1994;264:1918-1921.
63. van den Broek MF, Müller U, Huang S, Aguet M, Zinkernagel RM. Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors. J Virol 1995;69:4792-4796.
64. Zinkernagel RM. Immunology taught by viruses. Science 1996;271:173-178.
65. Blanden RV. T cell responses to viral and bacterial infection. Transplant Rev 1974;19:56-88.
66. O'Neill HC, Brenan M. A role for early cytotoxic T cells in resistance to ectromelia virus infection in mice. J Gen Virol 1987;68:2669-2673.
67. + T-cell-deficient mice survive inoculation with high doses of vaccinia virus and exhibit altered IgG responses. Proc Natl Acad Sci USA 1992;89:6070-6074.
68. Kägi D, et al. The roles of perforin- and Fas-dependent cytotoxicity in protection against cytopathic and noncytopathic viruses. Eur J Immunol 1995;25:3256-3262.
69. Kägi D, et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994;265:528-530.
70. + T lymphocytes and macrophage subsets in the control of a generalized virus infection. J Virol 1996;70:8301-8309.
71. Wong GHW, Taitaglia LA, Lee MS, Goeddel DV. Antiviral activity of tumor necrosis factor (TNF) is signaled through t he 55-kDa receptor, type I TNF. J Immunol 1992;149:3350-3353.
72. Rothe J, Mackay F, Bluethmann H, Zinkernagel R, Lesslauer W. Phenotypic analysis of TNFR!-deficient mice and characterization of TNFR1-deficient fibroblasts in vitro. Circ Shock 1994;44:51-56.
73. Grell M, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995;83:793-802.
74. Kopf M, Le Gros G, Bachmann M, Lamers MC, Bluethmann H, Kohler G. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 1993;362:245-248.
75. Bachmann MF, et al. Antiviral immune responses in mice deficient for both interleukin-2 and interleukin-4. J Virol 1995;69:4842-4846.
76. + T-cell responses in mice homozygous for disruption of the interleukin-4 gene. J Virol 1997;71:2518-2521.
77. Carding SR, Allan W, McMickle A, Doherty PC. Activation of cytokine genes in T cells during primary and secondary murine influenza pneumonia. J Exp Med 1993;177:475-482.
78. + B cells and lack eosinphilia but have normal antibody and cytotoxic T cell responses. Immunity 1996;4:15-24.
79. Beagley KW, et al. Recombinant murine IL-5 induces high rate IgA synthesis in cycling IgA-positive Peyer's patch B cells. J Immunol 1988;141:2035-2042.
80. Pockley AG, Montgomery PC. In vivo adjuvant effect of interleukins 5 and 6 on rat tear IgA antibody responses. Immunology 1991;73:19-23.
81. Takatsu K, et al. Interleukin-5, a T-cell-derived B-cell differentiation factor also induces cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1987;84:4234-4238.
82. Kopf M, et al. Impaired immune and acute phase responses in IL-6-deficient mice. Nature 1994;368:339-342.
83. Rocha B, Tanchot C, Von Boehmer H. Clonal anergy blocks in vivo growth of mature T cells and can be reversed in the absence of antigen. J Exp Med 1993;177:1517-1521.
84. Schönrich G, et al. Downregulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction. Cell 1991;65:293-304.
85. Webb S, Morris C, Sprent J. Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. Cell 1990;63:1249-1256.
86. Moskophidis D, Lechner F, Pircher H, Zinkernagel RM. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic T cells. Nature 1993;362:758-761.
87. Lamb JR, Feldmann M. A human suppressor T cell clone which recognises an autologous helper T cell clone. Nature 1982;300:456-458.
88. Miller RG. The veto phenomenon and T-cell regulation. Immunol Today 1986;7:112-114.
89. Ohashi P, et al. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991;65:305-317.
90. + T-cell deficient mice. J Virol 1994;68:4700-4704.
91. Penna A, et al. Cytotoxic T lymphocytes recognize an HLA-A2-restricted eiptope within the hepatitis B virus nucleocapsid antigen. J Exp Med 1991;174:1565-1570.
92. Nayersina R, et al. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol 1993;150:4649-4671.
93. Karupiah G, Harris N. Gamma interferon-induced nitric oxide in antiviral defense and immunopathology. In: Karupiah G, ed. Gamma Interferon in Antiviral Defense. Texas: RG. Landes Company; 1997. p. 119-142.
94. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997;15:323-350.
95. Rolph MS, Ramshaw IA, Rockett KA, Ruby J, Cowden WB. Nitric oxide production is increased during murine vaccinia virus infection, but may not be essential for virus clearance. Virology 1996;217:470-477.
96. Rolph MS, Cowden WB, Medveczky CJ, Ramshaw IA. A recombinant vaccinia virus encoding inducible nitric oxide synthase is attenuated in vivo. J Virol 1996;70:7678-7685.